• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 18, 2023 at 08:22: PM
via Novo Nordisk (NVO) stock skidded Monday on reports a Food and Drug Administration inspection turned up "objectionable conditions" at a facility charged with making diabetes and weight-loss drugs.

article source
 

<



Similar threads

cafead
Novo Nordisk bets $600M biobucks on NanoVation&#039;s ability to take genetic medicines beyond the liver
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Replies
0
Views
29
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Study backs role of Novo Nordisk obesity drug in children
Replies
0
Views
21
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk&#039;s Ozempic shortage expected to continue into Q4
Replies
0
Views
72
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk to build $220 mln raw materials plant in Denmark
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote